Short-term effects of nicotine on bone and calciotropic hormones in adult female rats

被引:18
作者
Fung, YK
Mendlik, MG
Haven, MC
Akhter, MP
Kimmel, DB
机构
[1] Univ Nebraska, Med Ctr, Coll Dent, Dept Oral Biol, Lincoln, NE 68583 USA
[2] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA
[3] Creighton Univ, Sch Med, Osteoporosis Res Ctr, Omaha, NE 68131 USA
来源
PHARMACOLOGY & TOXICOLOGY | 1998年 / 82卷 / 05期
关键词
D O I
10.1111/j.1600-0773.1998.tb01432.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study assessed the effects of two months nicotine treatment on bone formation and resorption end-points in adult, female rats. In addition, the concentrations of calciotropic hormones which included parathyroid hormone, calcitonin, 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in rats (7 months old) were determined. Ail animals received either saline (n = 7/group), nicotine (3.0 mg/kg/day) (n = 7/group) or nicotine (4.5 mg/kg/day) (n = 7/group) via subcutaneous implantation of osmotic minipumps containing either saline or nicotine for a period of two months. Serum, right tibia, left femur and lumbar vertebra (3-5) were collected for determination of hormonal concentrations as well as various parameters, including histomorphometry, bone mineral density, bone mineral content and vertebral strength. Although nicotine-treated rats showed a lower level of 25-hydroxyvitamin D [54.4+/-3.1 ng/ml for the 3.0 mg/kg/day and 55.8+/-2.8 for the 4.5 mg/kg/day group] (mean+/-S.E.M.) as compared to controls (74.8+/-2.8 ng/ml) (P<0.01, Newman-Keuls test), no significant difference could be detected for the levels of the remaining hormones. Similarly, no statistical differences were detected on histomorphometric end-points, bone mineral density, bone mineral content and vertebral strength of rats. We conclude that, in spite of lowering serum 25-hydroxyvitamin D by about 30%, nicotine administration of two months duration does not alter bone mass, strength or formation and resorption end-points.
引用
收藏
页码:243 / 249
页数:7
相关论文
共 54 条
[1]  
AVIOLI LV, 1984, ANNU REV NUTR, V4, P471, DOI 10.1146/annurev.nu.04.070184.002351
[2]   Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders [J].
Balfour, DJK ;
Fagerstrom, KO .
PHARMACOLOGY & THERAPEUTICS, 1996, 72 (01) :51-81
[3]  
BARON JA, 1995, J PHARMACOL EXP THER, V272, P151
[4]  
Baron R.A., 1983, BONE HISTOMORPHOMETR, P13
[5]  
BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318
[6]   DAILY USE OF SMOKELESS TOBACCO - SYSTEMIC EFFECTS [J].
BENOWITZ, NL ;
JACOB, P ;
YU, L .
ANNALS OF INTERNAL MEDICINE, 1989, 111 (02) :112-116
[7]  
BIKLE DD, 1994, RHEUM DIS CLIN N AM, V20, P759
[8]   THE EFFECT OF CHRONIC NICOTINE ADMINISTRATION ON BONE-MINERAL CONTENT IN MICE [J].
BROULIK, PD ;
JARAB, J .
HORMONE AND METABOLIC RESEARCH, 1993, 25 (04) :219-221
[9]  
CIVITELLI R, 1995, CALCIUM REGULATING H, P1